GlassScriptPhysician profile
Leonard Lefkovic
NPI 1548258270
$27,637.52
in general payments reported to CMS, 2019-2025
11 companies · $27.50 in 2025
The $27.50 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $3,504 · 2021: $2,045 · 2022: $74.47 · 2023: $426 · 2024: $329 · 2025: $27.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $783.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $782.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $25,847.99 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $697.92 | 2019-2024 | |
| Amgen INC. | $222.02 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $215.22 | 2019-2020 | |
| Medtronic, INC. | $189.59 | 2021-2023 | Corevalve Evolut R |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $141.58 | 2019-2020 | |
| Boston Scientific Corporation | $117.21 | 2024 | |
| Novo Nordisk INC | $114.08 | 2019 | |
| Pfizer INC. | $42.50 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.58 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $20.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Lefkovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.